Abstract
As degradation product of Antineoplaston A10 in vivo, phenylacetyl glutamine showed antitumor activities. According to literatures, we designed and radiosynthesized a phenylacetyl glutamine derivative, which was achieved under a mild reaction condition. Evaluations in vitro and in vivo were performed on tumor bearing mice. Excitingly, the radiochemical purity of (S)-2-((S)-2-(4-(3-fluoropropyl)benzamido)-3-phenylpropanamido)pentanedioic acid ([18F]FBPPA) was 98%, and besides the best radiochemical yield was up to 46%. T/Bl (Tumor/Blood) and T/M (Tumor/Muscle) ratios of [18F]FBPPA at 60 min post injection were 2.33 and 3.51. Meanwhile, it showed satisfied stability in vitro and in vivo, compared with 2-[18F]fluorodeoxyglucose ([18F]FDG). Although [18F]FBPPA deserved further studies to make optimizations on its structure, the results revealed it might become a potential PET imaging agent for detecting tumors.
Abbreviations
- [18F]FBPPA:
-
(S)-2-((S)-2-(4-(3-fluoropropyl)benzamido)-3-phenylpropanamido)pentanedioic acid
References
Thomas B, Christopher JRF, Andrew KJ (2008) Label Compd Radiopharm 51:369
Tetsuhiro H, Nobuyuki K, Yoshihiro N (2008) Eur J Nucl Med Mol Imaging 35:2009
Weiping Y, Larry W, Mark MG (2009) Bioorg Med Chem 17:1982
Patt M, Schildan A, Habermann B, Mishchenko O, Patt JT, Sabri O (2010) J Radioanal Nucl Chem 283:487
Burzynski SR (1983) Abstracts of papers Eur 13th Int Cong chemother[C]. Vienna, p 11
Khalid M (1987) Drugs Exptl Clin Res 13(Supp 1):57
Qu X, Cui S, Tiani Z (2007) Anticancer Res 27(4B):2427
Revelle LK, Avignon DAD, Wilson JA (1996) J Pharm Sci 85(10):1049
Eagel H (1957) Arch Bilphys 67:432
Furst P, Pogan K, Stehle P (1997) Nutrition 13(7–8):731
Curthoys NP, Watford M (1995) Ann Rev Nutr 15:133
Segura JA, Donadio AC, Lobo C (2005) Cancer Lett 218(1):91
Medina MA (2001) J Nutr 131(9 Suppl):2539S
Deberardinis RJ, Cheng T (2010) Oncogene 29(3):313
Byrne TA, Persinger RL, Young LS (1995) Ann Surg 222(3):243
Lohmann R, Souba WW, Zakrzewski (1998) Metab Clin Exp 47:608
Kung HF, Zhu L, Ploessl K (2009) Abstracts of papers 238th ACS national meeting, Wahington DC, USA, August 16–20. ACS, Wahington, DC, p 641
Dinkelborg L, Friebe M, Krasikowa R. WO Patent. 2008052788, 2008
Guan MY, Shi N, Sun JZ (2003) J Chin Clin Med Imaging 14(2):112
Chu TW, Xie JL, Wang XY (2002) Nucl Tech 25(5):361
Wang MW, Yin DZ, Zhang L (2006) Nucl Sci Tech 17(3):148
Zhao YL, Zhang CL, Qi CM (2007) J Radioanal Nucl Chem 273:9
Jinming Zhang, Yungang Li, Jian Liu (2010) J Radioanal Nucl Chem 283:565
Nandy SK, Krishnamurthy NV, Rajan MGR (2010) J Radioanal Nucl Chem 283:245
Coleman RE (2000) Imaging Nucl Med Bio 27:689
Li RF, Wu SC, Wang SC (2010) Appl Radiat Isot 68:303
Hoh CK (2007) Nucl Med & Bio 34:737
Qiao YL, He Y, Zhang S (2009) Bioorg Med Chem Lett 19:4873
Acknowledgments
We acknowledged with thanks for financial supports from the National Natural Science Foundation of China (No.20371009 and No.20671014), Key laboratory of Radioactive Medicine of Ministry Education and Beijing Municipal Commission of Education.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
He, Y., Ding, R., Liu, H. et al. (S)-2-((S)-2-(4-(3-[18F]fluoropropyl)benzamido)-3-phenylpropanamido)pentanedioic acid labeled with 18F. J Radioanal Nucl Chem 286, 135–140 (2010). https://doi.org/10.1007/s10967-010-0633-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-010-0633-2